Please use this identifier to cite or link to this item: http://nopr.niscpr.res.in/handle/123456789/12938
Full metadata record
DC FieldValueLanguage
dc.contributor.authorWang, Hong-yue-
dc.contributor.authorWang, Yan-jun-
dc.contributor.authorCui, Ming-ji-
dc.contributor.authorGu, Chun-mei-
dc.contributor.authorYang, Li-zhi-
dc.contributor.authorZhao, Ying-
dc.contributor.authorChen, Yan-
dc.contributor.authorZhao, Dan-
dc.contributor.authorLi, Tian-shu-
dc.contributor.authorChi, Bao-rong-
dc.date.accessioned2011-10-21T11:00:54Z-
dc.date.available2011-10-21T11:00:54Z-
dc.date.issued2011-10-
dc.identifier.issn0975-0959 (Online); 0301-1208 (Print)-
dc.identifier.urihttp://hdl.handle.net/123456789/12938-
dc.description308-315en_US
dc.description.abstractSeveral studies have shown that hepatocyte growth factor (HGF) ameliorates renal interstitial fibrosis, but the mechanism is not fully clear. This study was designed to examine whether HGF can relieve renal interstitial injury in 5/6 nephrectomized rats, and to confirm whether this function was associated with decrease in -smooth muscle actin (-SMA) and transforming growth factor-beta1 (TGF-1) expression. The animals were randomized into 8 groups comprising 6 animals (n = 6) each: control (group I), PCI-neo (group II, 900 μg), sham-operation (group III,not nephrectomy), model or 5/6 nephrectomy group (group IV), lotensin group (an angiotensin converting enzyme inhibitor, group V, 0.6 mg/100 g/day for 5 weeks), low-dose PCI-neo-HGF group (group VI, 690 μg), high-dose PCI-neo-HGF group (group VII, 1380 μg) and lotensin + high-dose PCI-neo-HGF group (group VIII, 0.6 mg/100 g/day for 5 weeks, 1380 μg). The animals were sacrificed in the 5th week after 5/6 nephrectomy. The specimens of kidneys were used for pathological examination (hematoxylin-eosin staining), detection of -SMA and TGF-1 mRNA (Reverse transcriptase-polymerase chain reaction) and protein (Western blot and immunohistochemistry) expression. The results showed that in 5/6 nephrectomized rats blood urea nitrogen (BUN), serum creatinine (CRE) and 24 h urinary albumin excretion (UAE) were increased, renal interstitium was injured seriously and -SMA, TGF-1 mRNA and protein expression were elevated compared with those of control. The above changes were ameliorated and -SMA and TGF-1 expression was reduced by both PCI-neo-HGF and lotensin. The lotensin + high-dose PCI-neo-HGF group rats exhibited the most significant therapeutic effect both in decreasing the BUN, CRE and 24 h UAE and in relieving renal interstitial injury. In conclusion, the study demonstrated that HGF can relieve renal interstitial injury and this protection was associated with down-regulation of –SMA and TGF-1 expressions.en_US
dc.language.isoen_USen_US
dc.publisherNISCAIR-CSIR, Indiaen_US
dc.rights CC Attribution-Noncommercial-No Derivative Works 2.5 Indiaen_US
dc.sourceIJBB Vol.48(5) [October 2011]en_US
dc.subjectPCI-neo-hepatocyte growth factoren_US
dc.subject5/6 Nephrectomized ratsen_US
dc.subjectTransforming growth factor-1en_US
dc.subject-Smooth muscle actinen_US
dc.titleHepatocyte growth factor-induced amelioration in renal interstitial fibrosis is associated with reduced expression of -smooth muscle actin and transforming growth factor-1en_US
dc.typeArticleen_US
Appears in Collections:IJBB Vol.48(5) [October 2011]

Files in This Item:
File Description SizeFormat 
IJBB 48(5) 308-315.pdf412.05 kBAdobe PDFView/Open


Items in NOPR are protected by copyright, with all rights reserved, unless otherwise indicated.